NEUROGENE INC (NGNE) Stock Overview
USA - NASDAQ:NGNE - US64135M1053 - Common Stock
NGNE Key Statistics, Chart & Performance
The current stock price of NGNE is 31.57 USD. In the past month the price increased by 79%. In the past year, price decreased by -32.67%.
NGNE Latest News, Press Relases and Analysis
NGNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.42 | 400.74B | ||
| AMGN | AMGEN INC | 13.41 | 157.41B | ||
| GILD | GILEAD SCIENCES INC | 15.24 | 146.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 106.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.22B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.47B | ||
| ARGX | ARGENX SE - ADR | 90.52 | 51.33B | ||
| INSM | INSMED INC | N/A | 35.13B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.77B | ||
| NTRA | NATERA INC | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.32B | ||
| BIIB | BIOGEN INC | 9.27 | 21.76B |
Related stock screener links
About NGNE
Company Profile
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 107
Phone: 18772375020
NEUROGENE INC / NGNE FAQ
What does NGNE do?
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Can you provide the latest stock price for NEUROGENE INC?
The current stock price of NGNE is 31.57 USD. The price increased by 1.77% in the last trading session.
What is the dividend status of NEUROGENE INC?
NGNE does not pay a dividend.
What is the ChartMill rating of NEUROGENE INC stock?
NGNE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for NGNE stock?
NEUROGENE INC (NGNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.31).
What is the market capitalization of NGNE stock?
NEUROGENE INC (NGNE) has a market capitalization of 450.50M USD. This makes NGNE a Small Cap stock.
What is the outstanding short interest for NEUROGENE INC?
The outstanding short interest for NEUROGENE INC (NGNE) is 22.06% of its float.
NGNE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE turns out to be only a medium performer in the overall market: it outperformed 50.18% of all stocks.
NGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NGNE. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability.
NGNE Financial Highlights
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS decreased by -7.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.38% | ||
| ROE | -24.21% | ||
| Debt/Equity | 0 |
NGNE Forecast & Estimates
13 analysts have analysed NGNE and the average price target is 48.35 USD. This implies a price increase of 53.15% is expected in the next year compared to the current price of 31.57.
For the next year, analysts expect an EPS growth of -12.75% and a revenue growth -100% for NGNE